



PROCEPT BioRobotics Corporation Announces Pricing of Upsized Initial Public Offering

September 14, 2021

REDWOOD CITY, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- [PROCEPT](#) BioRobotics Corporation (Nasdaq: PRCT) ("PROCEPT"), a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of its upsized initial public offering of 6,556,000 shares of its common stock at a public offering price of \$25.00 per share, for total gross proceeds of \$163.9 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by PROCEPT. PROCEPT's common stock is expected to begin trading on the Nasdaq Global Market on September 15, 2021, under the ticker symbol "PRCT." The offering is expected to close on September 17, 2021, subject to the satisfaction of customary closing conditions. In addition, PROCEPT has granted the underwriters a 30-day option to purchase up to an additional 983,400 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

BofA Securities and Goldman Sachs & Co. LLC are acting as joint lead bookrunning managers for the offering. Cowen, Guggenheim Securities and SVB Leerink are acting as co-managers.

Registration statements relating to the offering have been filed with the Securities and Exchange Commission and became effective on September 14, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained from: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About PROCEPT BioRobotics Corporation

[PROCEPT](#) is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the [AquaBeam Robotic System](#), an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed [Aquablation therapy](#) to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Forward Looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, and include, without limitation, statements regarding PROCEPT's expectations regarding the commencement of trading of its shares on the Nasdaq Global Market, the size, completion and timing of the closing of the offering. Forward-looking statements are based on PROCEPT's current expectations and assumptions and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Important factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions related to, and the completion of, the initial public offering. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the prospectus related to the initial public offering to be filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made only as of the date of this release, and PROCEPT undertakes no obligation to update such information except as required under applicable law.

Investor Contact:

Gilmartin Group
Matt Bacso, CFA
Matt.bacso@gilmartinir.com